• Publications
  • Influence
IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy
Hepatitis C virus (HCV) infects 3% of the world's population. Treatment of chronic HCV consists of a combination of PEGylated interferon-α (PEG-IFN-α) and ribavirin (RBV). To identify geneticExpand
  • 1,838
  • 92
Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies.
A large number of studies have reported on spontaneous viral clearance rates in acute hepatitis C infection, however most have been small, and reported rates have varied quite widely. To improve theExpand
  • 769
  • 32
Epidemiology and natural history of HCV infection
Worldwide, an estimated 130–170 million people have HCV infection. HCV prevalence is highest in Egypt at >10% of the general population and China has the most people with HCV (29.8 million).Expand
  • 704
  • 31
Estimation of stage‐specific fibrosis progression rates in chronic hepatitis C virus infection: A meta‐analysis and meta‐regression
Published estimates of liver fibrosis progression in individuals with chronic hepatitis C virus (HCV) infection are heterogeneous. We aimed to estimate stage‐specific fibrosis progression rates andExpand
  • 683
  • 25
Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind,
BACKGROUND Although the addition of the HCV NS3/4A protease inhibitors boceprevir and telaprevir to pegylated interferon (peginterferon) alfa plus ribavirin has improved sustained virologicalExpand
  • 443
  • 22
Estimating progression to cirrhosis in chronic hepatitis C virus infection
To gain a clearer understanding of the rate of progression to cirrhosis and its determinants in chronic hepatitis C virus (HCV) infection, a systematic review of published epidemiologic studies thatExpand
  • 605
  • 21
The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm.
The disease burden of hepatitis C virus (HCV) is expected to increase as the infected population ages. A modelling approach was used to estimate the total number of viremic infections, diagnosed,Expand
  • 371
  • 18
NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome.
BACKGROUND & AIMS The efficacy of NS5A inhibitors for the treatment of patients chronically infected with hepatitis C virus (HCV) can be affected by the presence of NS5A resistance-associatedExpand
  • 149
  • 16
Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study
BACKGROUND Hepatitis B and hepatitis C virus infections are common causes of death related to liver disease. In this large study, we aimed to investigate all cause mortality of the viruses in aExpand
  • 236
  • 15
Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States
Highly effective (cure rate >90%), once-daily, oral interferon-free treatments with minimal adverse effects are now available for hepatitis C virus (HCV) infection. Worldwide, an estimated 80 to 150Expand
  • 313
  • 14